WuXia TrueSite

Uncertainty in cell line performance can delay development, extend screening efforts, and disrupt downstream timelines. This video explores a targeted integration cell line platform built to introduce predictability early in development. By placing the gene of interest at a defined genomic “golden address,” the approach minimizes clone screening while enabling reliable, high‑level expression.

The result is consistent fed‑batch titers, strong monomeric purity, and robust performance across monoclonal and bispecific antibody programs. Viewers will also learn how this precision supports long‑term genetic stability over multiple generations. By compressing cell line development timelines, the platform helps relieve a critical CMC bottleneck, enabling earlier non‑GMP production and smoother transitions toward clinical milestones.

Watch the video to see how targeted integration brings speed, control, and confidence to cell line development.